# Senate HELP Seeks Healthcare AI Input

The Senate HELP Committee released a discussion draft of the PATIENT AI Act proposing clearer FDA and ONC oversight boundaries for AI-based health products, rolling FDA review of software changes, expanded HHS use of AI with privacy and security guidance, and a reimbursement pathway for AI tools. The draft is open for stakeholder comments through **December 1, 2026 (27 days from November 4)**; it is a proposal, not enacted law. Separately, a House proposal would require clinician review of AI-involved medical-necessity denials.

- Healthcare AI, clinical software, and health IT contractors can submit comments by December 1 on the draft’s oversight, software-update review, privacy, security, and reimbursement provisions.
- Companies should assess how the proposed FDA/ONC division and rolling review approach could affect product development, change management, and regulatory planning; the draft does not establish current requirements.
- The proposed reimbursement pathway could affect the business case for AI-enabled health tools. Contractors should evaluate its potential relevance to product offerings and reimbursement strategies.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Artificial Intelligence, Policy
**Published:** November 03, 2026

### Government Entities
- Senate Committee on Health, Education, Labor and Pensions (Senate HELP Committee)
- Food and Drug Administration (FDA)
- Office of the National Coordinator for Health Information Technology (ONC)
- Department of Health and Human Services (HHS)
- U.S. House of Representatives

### Key Quotes
> While AI can help make the claims process more efficient, it should never have the final say in denying someone access to medically necessary care.
> — Buddy Carter, U.S. Representative

### Sources
- [Senate Draft Bill Seeks Inputs on Healthcare AI Oversight](https://www.executivegov.com/articles/senate-patient-ai-act-healthcare-ai-discussion-draft) - ExecutiveGov